Metformin modulates autophagy in heterozygous and CRISPR-edited TSC2 primary fibroblasts

Imagine your body is a bustling, high-tech city. Inside every building (your cells), there's a master control room called mTORC1. This control room is like a super-energetic foreman who tells the construction crews to keep building new parts and eating up supplies. Usually, this is great, but if the foreman gets too hyperactive, he orders too much construction and stops the city's recycling crew from cleaning up old, broken machinery. This "recycling crew" is called autophagy. When autophagy stops working, trash piles up, and the city starts to get sick, forming unwanted lumps called tumors.

Now, imagine a specific genetic disorder called Tuberous Sclerosis Complex (TSC). In people with TSC, the "brakes" on that hyperactive foreman are broken. This happens because of a glitch in a gene called TSC2. Usually, scientists thought you needed to break both copies of the brake (a "two-hit" model) for the city to really fall apart. But this paper asks a tricky question: What if breaking just one copy (a "half-broken" brake, or haploinsufficiency) is enough to mess up the recycling crew, even before the second copy breaks? And, can we fix the recycling crew with a common, cheap medicine called metformin, which is usually used for diabetes?

This study dives into that question using tiny cells grown in a lab. The researchers took skin cells from people with TSC (who have one broken copy of the gene) and used a molecular "scissors" tool called CRISPR to cut the second copy, simulating the worst-case scenario where both brakes are gone. They then tested if drugs like rapamycin (a known brake for the foreman) and metformin could get the recycling crew working again.

Here is what they found:

First, they confirmed that having just one broken copy of the TSC2 gene is indeed enough to slow down the recycling crew. In the cells with one broken copy, the recycling (autophagy) was already struggling compared to healthy cells. When they used the molecular scissors to break the second copy (simulating the "two-hit" scenario), the problem got even worse, and the cells became even more desperate for a fix.

Next, they tested the treatments. They found that rapamycin worked well, as expected, helping the cells start recycling again. But the exciting discovery was about metformin. In the cells with just one broken copy, metformin successfully woke up the recycling crew, increasing the number of "cleaning trucks" (autophagosomes) by about 17.6% in one group of cells and 13.3% in another, compared to cells that got no treatment.

However, there was a twist. In the cells with a specific "uncertain" genetic glitch (called a VUS), metformin didn't work at all when the cells still had one good copy of the gene. It was like the recycling crew was too confused to listen to the new manager. But, the moment the researchers used CRISPR to break the second copy in those same cells, metformin suddenly worked! It restored the recycling ability, suggesting that some genetic glitches are so subtle that you only see their full effect when the backup copy is also lost.

The researchers also looked at the cells under a microscope. They saw that treated cells looked smaller and had more recycling bubbles inside them, which is a good sign. They also checked a protein called p-S6K, which acts like a "busy signal" for the cell. When the treatments worked, this busy signal went down, confirming that the cell's overactive construction mode had been dialed back.

In short, this paper suggests that having just one broken TSC2 gene is enough to disrupt the cell's cleaning system, and that metformin might be a powerful tool to fix this, even before the disease gets worse. While the study shows these effects clearly in lab-grown cells, the authors suggest that this could open a new door for treating TSC, offering a way to boost the cell's natural cleaning power using a drug that is already familiar and safe for many people.